Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
10 03 2023
10 03 2023
Historique:
received:
12
12
2022
accepted:
23
02
2023
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
The rapid spread of the SARS-CoV-2 Omicron subvariants, despite the implementation of booster vaccination, has raised questions about the durability of protection conferred by current vaccines. Vaccine boosters that can induce broader and more durable immune responses against SARS-CoV-2 are urgently needed. We recently reported that our Beta-containing protein-based SARS-CoV-2 spike booster vaccine candidates with AS03 adjuvant (CoV2 preS dTM-AS03) elicited robust cross-neutralizing antibody responses at early timepoints against SARS-CoV-2 variants of concern in macaques primed with mRNA or protein-based subunit vaccine candidates. Here we demonstrate that the monovalent Beta vaccine with AS03 adjuvant induces durable cross-neutralizing antibody responses against the prototype strain D614G as well as variants Delta (B.1.617.2), Omicron (BA.1 and BA.4/5) and SARS-CoV-1, that are still detectable in all macaques 6 months post-booster. We also describe the induction of consistent and robust memory B cell responses, independent of the levels measured post-primary immunization. These data suggest that a booster dose with a monovalent Beta CoV2 preS dTM-AS03 vaccine can induce robust and durable cross-neutralizing responses against a broad spectrum of variants.
Identifiants
pubmed: 36894558
doi: 10.1038/s41467-023-36908-z
pii: 10.1038/s41467-023-36908-z
pmc: PMC9998256
doi:
Substances chimiques
COVID-19 Vaccines
0
Broadly Neutralizing Antibodies
0
Protein Subunits
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1309Informations de copyright
© 2023. The Author(s).
Références
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2022 Dec 15;387(24):2203-2206
pubmed: 36507702
Sci Transl Med. 2022 Aug 17;14(658):eabq4130
pubmed: 35976993
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
N Engl J Med. 2022 Jul 28;387(4):374-376
pubmed: 35767474
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Nat Rev Immunol. 2015 Mar;15(3):149-59
pubmed: 25677494
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
NPJ Vaccines. 2021 Dec 21;6(1):158
pubmed: 34934069
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Lancet Infect Dis. 2022 May;22(5):636-648
pubmed: 35090638
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315825
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Nat Commun. 2022 Mar 31;13(1):1699
pubmed: 35361754
Nature. 2023 Feb;614(7948):521-529
pubmed: 36535326
Nat Rev Immunol. 2020 Apr;20(4):229-238
pubmed: 31836872
N Engl J Med. 2023 Feb 9;388(6):567-569
pubmed: 36630643
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
J Cell Mol Med. 2022 Feb;26(4):1293-1305
pubmed: 35043552
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
J Immunol. 2022 Feb 15;208(4):819-826
pubmed: 35039333
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Nat Commun. 2022 Oct 2;13(1):5794
pubmed: 36184631
NPJ Vaccines. 2021 Apr 19;6(1):61
pubmed: 33875658